Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Upgraded by Wall Street Zen

Tiziana Life Sciences (NASDAQ:TLSA) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

TLSA has been the topic of a number of other reports. Weiss Ratings upgraded Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 19th. BTIG Research reissued a “buy” rating on shares of Tiziana Life Sciences in a report on Tuesday, September 22nd. Finally, Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Tiziana Life Sciences Price Performance

Shares of TLSA opened at $0.95 on Friday. The stock’s 50 day moving average is $1.03 and its two-hundred day moving average is $1.15. Tiziana Life Sciences has a twelve month low of $0.76 and a twelve month high of $2.10.

Insider Activity at Tiziana Life Sciences

In other news, CEO Ivor Elrifi purchased 237,616 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $1.00 per share, for a total transaction of $237,616.00. Following the acquisition, the chief executive officer directly owned 4,793,684 shares in the company, valued at approximately $4,793,684. The trade was a 5.22% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders purchased 988,423 shares of company stock worth $985,909. 39.82% of the stock is owned by insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC raised its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 12.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 111,900 shares of the company’s stock after purchasing an additional 12,000 shares during the period. Zhang Financial LLC owned about 0.09% of Tiziana Life Sciences worth $131,000 at the end of the most recent reporting period.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapies that modulate the immune system to treat neuroinflammatory and neurodegenerative diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody designed to target the CD3 receptor on T cells and potentially reduce harmful immune activation.

Tiziana is primarily evaluating an intranasal formulation of foralumab in conditions involving inflammation of the central nervous system, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.